Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9H3H5: Variant p.Val264Gly

UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase
Gene: DPAGT1
Feedback?
Variant information Variant position: help 264 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Valine (V) to Glycine (G) at position 264 (V264G, p.Val264Gly). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (V) to glycine (G) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CMS13; increased UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase activity. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 264 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 408 The length of the canonical sequence.
Location on the sequence: help YPSRVFVGDTFCYFAGMTFA V VGILGHFSKTMLLFFMPQVF The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         YPSRVFVGDTFCYFAGMTFAVVGILGHFSKTMLLFFMPQVF

Mouse                         YPSRVFVGDTFCYFAGMTFAVVGILGHFSKTMLLFFMPQVF

Bovine                        YPSRVFVGDTFCYFAGMTFAVVGILGHFSKTMLLFFMPQVF

Slime mold                    YPSRVFVGDTYTYFSGMCFAVVAILCHFSKTLLLFFIPQIL

Baker's yeast                 WPATVFVGDTYCYFAGMVFAVVGILGHFSKTMLLLFIPQIV

Fission yeast                 WPSRVFVGDTFCYFAGMVMAVVGILGHFSKTLMLFFIPQIF
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 408 UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase
Transmembrane 251 – 269 Helical; Name=Helix 8
Binding site 252 – 252
Binding site 252 – 252
Mutagenesis 252 – 252 D -> A. Reduces binding to inhibitor. Nearly abolishes UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase activity.
Mutagenesis 264 – 264 V -> M. No significant effect on UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase activity.
Helix 251 – 269



Literature citations
Structures of DPAGT1 Explain Glycosylation Disease Mechanisms and Advance TB Antibiotic Design.
Dong Y.Y.; Wang H.; Pike A.C.W.; Cochrane S.A.; Hamedzadeh S.; Wyszynski F.J.; Bushell S.R.; Royer S.F.; Widdick D.A.; Sajid A.; Boshoff H.I.; Park Y.; Lucas R.; Liu W.M.; Lee S.S.; Machida T.; Minall L.; Mehmood S.; Belaya K.; Liu W.W.; Chu A.; Shrestha L.; Mukhopadhyay S.M.M.; Strain-Damerell C.; Chalk R.; Burgess-Brown N.A.; Bibb M.J.; Barry Iii C.E.; Robinson C.V.; Beeson D.; Davis B.G.; Carpenter E.P.;
Cell 175:1045-1058(2018)
Cited for: X-RAY CRYSTALLOGRAPHY (3.10 ANGSTROMS) OF WILD-TYPE AND VARIANT CMS13 GLY-264 IN COMPLEXES WITH UDP-N-ACETYLGLUCOSAMINE AND TUNICAMYCIN; FUNCTION; CATALYTIC ACTIVITY; BIOPHYSICOCHEMICAL PROPERTIES; COFACTOR; PATHWAY; ACTIVITY REGULATION; SUBUNIT; TOPOLOGY; CHARACTERIZATION OF VARIANT CDG1J CYS-170; CHARACTERIZATION OF VARIANTS CMS13 ILE-108; MET-120; SER-160; LEU-168; ILE-171; SER-192 AND GLY-264; MUTAGENESIS OF PRO-30; ILE-69; LEU-103; ALA-114; ASP-115; ASP-116; TRP-122; LYS-125; LEU-168; ASN-182; ASN-185; ASP-252; VAL-264; ARG-301; HIS-302; ARG-303 AND LEU-385; Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates.
Belaya K.; Finlayson S.; Slater C.R.; Cossins J.; Liu W.W.; Maxwell S.; McGowan S.J.; Maslau S.; Twigg S.R.; Walls T.J.; Pascual Pascual S.I.; Palace J.; Beeson D.;
Am. J. Hum. Genet. 91:193-201(2012)
Cited for: VARIANTS CMS13 ILE-108; ILE-117; MET-120; SER-160; SER-192 AND GLY-264;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.